Thursday, July 3, 2025
21.8 C
Srinagar

Natco’s marketing partner Alvogen receives USFDA approval for chest pain tablets

Mumbai,  : Pharma Major Natco Pharma Limited said that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the USFDA for chest pain tablets.
The company has received the final approval of Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, Natco Pharma said in a BSE filing.
Pfizer Pharmaceuticals Ltd markets this drug under its brand Nitrostat Sublingual Tablets in the same strengths mentioned above.
As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018.
(UNI)

Hot this week

As of now, no plans to extend summer vacation: J&K Education Minister Sakina Itoo

Srinagar, July 2: Jammu and Kashmir Education Minister Sakina Itoo...

Kralpora Women Protest With Empty Buckets Over Water Crisis “No Water for Months”

Handwara, Jul 2,: Amid an ongoing heatwave, dozens of...

J&K DGP reviews yatra security at Nayvug tunnel in Qazigund

Qazigund, July 02 : Director General of Police, Jammu...

Topics

spot_img

Related Articles

Popular Categories

spot_imgspot_img